Literature DB >> 23299358

Economic analysis of soft-heel casting for diabetic foot ulcer: prevention and treatment.

J Craig1, R Shenton, A Smith.   

Abstract

OBJECTIVE: To model the benefit of an innovative measure to manage patients with diabetes and a foot ulcer, or at high risk of ulceration, using a soft-heel casting, which can be applied by a podiatrist or other trained staff member and used in the hospital or community setting.
METHOD: An audit of the patient outcomes associated with the casting at NHS Borders was undertaken for inpatients with ulcers. These data were combined with other published data and expert opinion to model the benefit of the casting for prevention and curative purposes compared to standard practice. Cost of healed and unhealed ulcers in various settings was estimated based on the treatment pathways adopted.
RESULTS: The data from the economic model suggest that soft-heel castings could reduce the costs of managing these patients by approximately 10%; about £500 per inpatient and £425 per outpatient with an ulcer, and £205 per high-risk patient, when used for prevention.
CONCLUSION: This cost-consequence analysis suggests the intervention could save about 10% of costs for managing patients with an active ulcer in inpatients or outpatients and offers potential savings if used as a preventive measure. Further studies are required to confirm the estimated clinical benefit and reduced resource use.

Entities:  

Mesh:

Year:  2013        PMID: 23299358     DOI: 10.12968/jowc.2013.22.1.44

Source DB:  PubMed          Journal:  J Wound Care        ISSN: 0969-0700            Impact factor:   2.072


  2 in total

1.  Fibreglass Total Contact Casting, Removable Cast Walkers, and Irremovable Cast Walkers to Treat Diabetic Neuropathic Foot Ulcers: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2017-09-21

2.  Is Reconstruction of Unstable Midfoot Charcot Neuroarthropathy Cost Effective from a US Payer's Perspective?

Authors:  Rachel H Albright; Robert M Joseph; Dane K Wukich; David G Armstrong; Adam E Fleischer
Journal:  Clin Orthop Relat Res       Date:  2020-12       Impact factor: 4.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.